Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol
This article was originally published in The Tan Sheet
Executive Summary
Evaluation of naproxen safety should be postponed until final data from NIH's ADAPT trial is released, Cleveland Clinic cardiologist Eric Topol, MD, advocates